1. What Constitutes False or Misleading Advertising under Federal and State Law?
False advertising claims typically arise under the Lanham Act (15 U.S.C. § 1125(a)), which prohibits any representation that is likely to deceive consumers about material facts regarding origin, sponsorship, approval, or characteristics of goods or services. State consumer protection statutes and common law fraud principles often provide parallel grounds for suit. Courts focus on whether the challenged claim is literally false or, if not literally false, whether it is likely to mislead a reasonable consumer. The Lanham Act standard does not require proof of actual consumer deception; rather, the plaintiff must establish that the claim is likely to deceive. In practice, these cases are rarely as clean as the statute suggests because courts wrestle with what reasonable consumer means and whether context matters.
How Do Courts Evaluate Reasonable Consumer Deception?
The reasonable consumer test examines whether the advertisement, taken as a whole and in context, conveys a false message about a material fact. Courts consider the target audience, the medium of advertising, and the sophistication of consumers in the relevant market. An exaggerated or puffery claim (e.g., best in class) is generally not actionable, but a specific factual assertion (e.g., clinically proven to reduce wrinkles by 50%) without adequate substantiation can trigger liability. The Second Circuit and federal courts in New York have emphasized that substantiation requirements vary by industry; pharmaceutical and dietary supplement advertising face heightened scrutiny under FDA standards, while other sectors may have looser standards. For example, in SDNY litigation involving skincare products, defendants have faced summary judgment denials when unable to produce adequate clinical data supporting quantified efficacy claims.
What Role Does Regulatory Compliance Play in Advertising Disputes?
Federal Trade Commission (FTC) standards, FDA regulations, and state attorney general enforcement create overlapping compliance obligations. Even if a private competitor does not bring suit, FTC investigations or state consumer protection actions can result in consent decrees, corrective advertising orders, and civil penalties. The FTC's Endorsement Guides and standards for substantiation are frequently cited in private litigation as evidence of industry norms. From a practitioner's perspective, advertising disputes often accelerate when regulatory agencies become involved because defendants face both private litigation and administrative proceedings simultaneously.
2. What Are the Primary Defenses in Advertising Litigation?
Defendants in advertising litigation typically pursue one or more of the following defenses: (1) the claim is not literally false and is not likely to deceive; (2) the claim is non-actionable puffery or opinion; (3) the claim is substantiated by competent and reliable evidence; (4) the plaintiff lacks standing or fails to prove injury; or (5) the statement is protected speech under the First Amendment. The Lanham Act requires a plaintiff to prove injury (typically lost sales or diverted customers), though some courts infer injury from likelihood of deception. Standing issues frequently arise when a competitor alleges deception but has not suffered direct competitive harm or when a consumer lacks privity with the defendant.
How Do Courts in New York Handle Injunctive Relief in Advertising Cases?
Preliminary injunctive relief is a critical battleground in advertising litigation. Courts in the Southern District of New York and state courts apply the traditional four-factor test: likelihood of success on the merits, likelihood of irreparable harm, balance of equities, and public interest. In advertising cases, irreparable harm is often presumed because the defendant's continued use of allegedly false claims can damage the plaintiff's reputation and market position in ways that monetary damages cannot fully remedy. However, courts are increasingly skeptical of automatic irreparable harm findings and require specific evidence of ongoing competitive injury. The practical significance is that a defendant facing a preliminary injunction motion must prepare detailed evidence of substantiation and non-deceptiveness early in the litigation because delays in discovery can result in an adverse preliminary ruling that effectively ends the case.
3. How Should You Approach Settlement and Damage Exposure in These Disputes?
Damages in advertising litigation can include lost profits, unjust enrichment, corrective advertising costs, and statutory penalties under state consumer protection laws. Under the Lanham Act, a prevailing plaintiff may recover defendant's profits, treble damages, and attorney fees if the court finds the violation willful. Actual damages are often difficult to quantify, which creates settlement leverage for both sides. Early assessment of substantiation records, competitor evidence, and consumer complaint data is critical for evaluating settlement posture. Many advertising disputes settle before trial because of the uncertainty in proving both liability and damages, but the negotiation requires clear-eyed analysis of injunctive risk and reputational exposure.
What Discovery Issues Commonly Arise in Advertising Litigation?
Discovery in advertising cases typically focuses on: (1) the creation and approval process for the challenged advertisement; (2) internal communications discussing substantiation or consumer testing; (3) sales data and market research; and (4) prior complaints or regulatory inquiries. Defendants often face significant exposure if internal emails reveal awareness of lack of substantiation or knowledge of deceptiveness. The table below outlines key discovery priorities:
| Discovery Category | Typical Scope | Risk Area |
| Advertising Creation | Scripts, copywriting, design decisions, approval chain | Admissions of intent to deceive or reckless disregard |
| Substantiation Records | Clinical studies, testing reports, expert opinions, vendor communications | Gaps or weakness in support for challenged claims |
| Consumer Feedback | Complaints, returns, social media, customer service logs | Evidence of actual consumer confusion |
| Competitive Intelligence | Monitoring of competitor ads, market analysis, pricing comparisons | Evidence of intent to disparage or mislead |
4. When Should You Involve Counsel in Advertising Disputes?
Legal counsel should be engaged immediately upon receipt of a cease-and-desist letter, regulatory inquiry, or notice of competitive challenge. Early involvement allows counsel to assess substantiation adequacy, evaluate injunctive risk, and preserve privilege over internal communications. Waiting to respond or attempting internal resolution often results in waiver of attorney-client privilege and loss of strategic options. The intersection of advertising and marketing law with regulatory compliance and intellectual property issues means that multidisciplinary coordination is often necessary. Additionally, if your company operates across multiple states or involves FDA-regulated products, advertising, marketing, and promotions law counsel should evaluate compliance with state-specific consumer protection statutes and FTC standards before litigation erupts. The key strategic decision is whether to defend the claim on the merits, seek early settlement, or pursue a regulatory defense strategy in parallel with private litigation.
Moving forward, prioritize a comprehensive audit of your current advertising claims and substantiation records. Identify which claims are most vulnerable to challenge and which are well-supported by evidence. Establish a protocol for approval of new advertising materials that includes legal review and substantiation verification before launch. If you are already facing a dispute, request that counsel conduct a privilege-protected assessment of your litigation posture and settlement value so that you can make informed decisions about resource allocation and risk tolerance.
02 Apr, 2026
